Field trials were conducted at the University of Kentucky Research and Education Center in Princeton, Kentucky, in 2016, using KTD14LC in both dark air-cured (DAC) and dark fire-cured (DFC) trials. The trial was repeated in 2017 at Princeton KY, Lexington KY, and Murray KY and included additional varieties of NL MadoleHC in the dark trials, and TN90LC, and TN90HC in the Burley trials. Potassium chloride (KCl) and potassium sulfate (K₂SO₄) were used as potassium sources. Treatments were arranged in a randomized complete block design with four replications, including an untreated check. Potassium sources were broadcast applied prior to transplanting at 112, 224, and 336 kg K₂O ha^-1, respectively. In 2016, the DAC trial had significantly lower TSNA levels than the DFC trial. In the DAC trial, KCl showed to have significantly lower TSNA levels than those of K₂SO₄ however, KCl had a significantly higher yield than K₂SO₄. In 2017, both potassium sources yielded higher than the untreated check. KTD14LC had higher yields than the NL MadoleHC. In three of the four dark trials, KCl showed a higher-grade index (GI). In the DFC Princeton trial, GI increased as potassium levels increased. In the Burley trial there was a rate response, the untreated check yielded less than the other treatments except for the KCl treatment at 112 kg ha^-1. All three locations showed that KCl treatments had lower TSNA compared to K₂SO₄. In 2017 at Princeton, KCl had a 42 % reduction of TSNA in the DAC trail, and a 32 % reduction in the DFC trial as compared to K₂SO₄. At Murray, KCl treatments had a reduction of 7 % in TSNA in the DAC trial, and a 24 % reduction in the DFC trial compared to K₂SO₄. The Burley trial KCl treatments had a 31 % reduction in TSNA compared to K₂SO₄ treatments.